Syra Health Corp. Class A (SYRA) Cash Flow Statement
Where SYRA’s cash came from and went, 2025
December 31, 2025 · U.S. dollars- Cash from operations
- −$447,746
- Capital expenditures
- $107 0.0% of revenue
- Free cash flow
- −$447,853 −6.2% margin
- Returned to shareholders
- —
- Change in cash
- −$780,672 cash at year-end $1.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
SYRA operating cash flow, capex and free cash flow
SYRA cash flow trends, 2021–2025
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$88,1992021 | −$447,7462025 | — | |
| Capital expenditures | $6,2892021 | $1072025 | −63.9%/yr | |
| Free cash flow | −$94,4882021 | −$447,8532025 | — | |
| Free cash flow margin | −6.7%2021 | −6.2%2025 | +0.5 pts | |
| Stock-based compensation | $02021 | $98,5542025 | — | |
| Capex / revenue | 0.4%2021 | 0.0%2025 | −0.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
SYRA cash flow by activity
SYRA net income vs operating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
SYRA cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Operating activities | |||||
| Net income | −$896,333 | −$3.8M | −$2.9M | −$2.1M | −$3,280 |
| Depreciation & amortization | $20,468 | $62,738 | $48,771 | $14,849 | $207 |
| Stock-based compensation | $98,554 | $59,803 | $32,831 | $2,910 | $0 |
| Change in working capital | $326,979 | $543,786 | −$23,416 | −$763,298 | −$112,385 |
| Other non-cash items | $2,586 | $160,878 | $121,089 | $619,639 | $27,259 |
| Cash from operating activities | −$447,746 | −$2.9M | −$2.8M | −$2.2M | −$88,199 |
| Investing activities | |||||
| Capital expenditures | −$107 | −$11,111 | −$15,251 | −$121,260 | −$6,289 |
| Investments (net) | — | −$11,111 | −$15,251 | −$121,260 | −$6,289 |
| Acquisitions & other investing | $0 | $11,111 | $15,251 | $121,260 | $6,289 |
| Cash from investing activities | −$107 | −$11,111 | −$15,251 | −$121,260 | −$6,289 |
| Financing activities | |||||
| Net borrowing (repayment) | −$347,619 | −$410,676 | $518,757 | $736,475 | $300 |
| Shares issued | $14,800 | $2.5M | $5.3M | $2.3M | $0 |
| Other financing | $0 | $0 | $200,010 | −$790,318 | $191,200 |
| Cash from financing activities | −$332,819 | $2.1M | $6.1M | $2.3M | $191,500 |
| Summary | |||||
| Net change in cash | −$780,672 | −$884,670 | $3.3M | −$96,668 | $97,012 |
| Cash at end of period | $1.6M | $2.4M | $3.3M | $3,344 | $100,012 |
| Free cash flow | −$447,853 | −$2.9M | −$2.8M | −$2.4M | −$94,488 |
| Free cash flow margin | −6.2% | −36.9% | −50.3% | −42.1% | −6.7% |
| Capex / revenue | 0.0% | 0.1% | 0.3% | 2.2% | 0.4% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | $250,242 | $240,979 | −$853,866 | $214,899 | −$63,596 | −$472,265 | −$504,397 | −$417,535 | −$1.4M | −$1.4M | −$995,275 | −$354,376 |
| Depreciation & amortization | $741 | $1,054 | $5,479 | $4,096 | $5,978 | $6,797 | $7,278 | $25,541 | $17,374 | $12,545 | $12,358 | $12,357 |
| Stock-based compensation | $21,095 | $23,344 | $43,744 | $10,933 | $21,123 | $32,944 | $31,317 | $0 | $14,346 | $14,140 | $29,162 | $1,079 |
| Change in working capital | −$990,840 | $1.1M | −$180,279 | −$44,929 | −$35,982 | $588,169 | $228,050 | −$58,204 | −$195,432 | $569,372 | −$703,203 | −$58,809 |
| Other non-cash items | $0 | $0 | $695,730 | −$429,307 | $0 | $2,586 | $23,032 | $36,897 | $50,701 | $50,248 | −$100,084 | $30,486 |
| Cash from operating activities | −$718,762 | $1.4M | −$289,192 | −$244,308 | −$72,477 | $158,231 | −$214,720 | −$413,301 | −$1.5M | −$800,745 | −$1.8M | −$369,263 |
| Investing activities | ||||||||||||
| Capital expenditures | −$5 | −$5 | −$108 | $0 | $0 | $0 | $0 | −$1 | −$5,492 | −$5,619 | $0 | −$3 |
| Investments (net) | — | — | — | $0 | $0 | $0 | $0 | $0 | −$5,492 | −$5,619 | $0 | $0 |
| Acquisitions & other investing | — | — | $1 | — | — | — | — | — | $5,492 | $5,619 | — | — |
| Cash from investing activities | — | — | −$107 | — | — | — | — | — | −$5,492 | −$5,619 | — | — |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −$79,809 | −$54,360 | −$72,513 | −$85,071 | −$112,184 | −$77,851 | −$87,334 | −$102,613 | — | — | — | — |
| Shares issued | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $5.3M | $0 |
| Other financing | $0 | $0 | $0 | $0 | $0 | $14,800 | $0 | $1.6M | −$134,846 | $764,246 | −$313,176 | $350,824 |
| Cash from financing activities | −$79,809 | −$54,360 | −$72,513 | −$85,071 | −$112,184 | −$63,051 | −$87,334 | $1.5M | −$134,846 | $764,246 | $5.0M | $350,824 |
| Summary | ||||||||||||
| Net change in cash | −$798,571 | $1.3M | −$361,812 | −$329,379 | −$184,661 | $95,180 | −$302,054 | $1.1M | −$1.6M | −$42,118 | $3.3M | −$18,439 |
| Cash at end of period | $2.1M | $2.9M | $1.6M | $2.0M | $2.3M | $2.5M | $2.4M | $2.7M | $1.6M | $3.2M | $3.3M | $18,010 |
| Free cash flow | −$718,757 | $1.4M | −$289,300 | −$244,310 | −$72,477 | $158,231 | −$214,720 | −$413,300 | −$1.5M | −$806,364 | −$1.8M | −$369,263 |
| Free cash flow margin | −30.0% | 59.9% | −16.7% | −14.5% | −3.7% | 8.5% | −10.7% | −18.3% | −76.6% | −46.0% | −99.5% | −23.4% |
| Capex / revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.3% | 0.3% | 0.0% | 0.0% |
| Operating cash flow / net income | −2.87 | 5.65 | — | −1.14 | — | — | — | — | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
SYRA cash generation
In fiscal 2025 (ended December 31, 2025), Syra Health Corp. Class A generated -$0.4 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of -$0.4 million, −6.2% of revenue. Cash and equivalents fell by $0.8 million over the year.
Related: SYRA income statement, SYRA balance sheet. See the SYRA stock overview for the latest quote and news.
SYRA cash flow FAQ
What is Syra Health Corp. Class A's free cash flow?
Syra Health Corp. Class A's free cash flow was -$0.4 million in fiscal 2025: -$0.4 million of operating cash flow minus $0.0 million of capital expenditures It was -$2.9 million a year earlier..
How much cash does Syra Health Corp. Class A generate from operations?
Syra Health Corp. Class A generated -$0.4 million of cash from operating activities in fiscal 2025.
How much does Syra Health Corp. Class A spend on capital expenditures?
Syra Health Corp. Class A spent $0.0 million on capital expenditures in fiscal 2025, 0.0% of revenue, compared with $0.0 million the year before.